

1 / 14

4

Name of Journal: *World Journal of Clinical Cases***Manuscript NO:** 56087**Manuscript Type:** CASE REPORT

**Lung adenocarcinoma harboring rare epidermal growth factor receptor
L858R and V834L mutations treated with icotinib: A case report**

Shu-Sen Zhai, Hui Yu, Tian-Tian Gu, Yan-Xia Li, Yan Lei, Hai-Yan Zhang,
Tong-Huan Zhen, Yun-Ge Gao

Abstract

BACKGROUND

Match Overview

- | Match Number | Source | Words | Crawled On | URL | Similarity |
|--------------|----------|----------|------------------------|--|------------|
| 1 | Internet | 28 words | crawled on 13-Apr-2020 | www.cjcrn.org | 1% |
| 2 | Internet | 17 words | crawled on 07-Apr-2020 | www.dovepress.com | 1% |
| 3 | Internet | 16 words | crawled on 14-Apr-2020 | www.nice.org.uk | 1% |
| 4 | Internet | 14 words | crawled on 28-May-2020 | f6publishing.blob.core.windows.net | 1% |
| 5 | Crossref | 12 words | | Xi Li, Li Zhang, Da Jiang, Yan Wang et al. "Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients" | 1% |



激活 Windows
转到“设置”以激活 Windows。



Lung adenocarcinoma harboring rare epidermal growth factor rece



ALL IMAGES VIDEOS MAPS NEWS SHOPPING

4,420 Results Any time ▾

Rare epidermal growth factor receptor (EGFR) mutations in ...

<https://www.sciencedirect.com/science/article/pii/S1044579X19303025>

Apr 01, 2020 · **Epidermal growth factor receptor (EGFR) mutations** are the second most common oncogenic driver event in non-small cell **lung** cancer (NSCLC). Classical activating **mutations** (exon 19 deletions and the **L858R** point mutation) comprise the vast majority of EGFR **mutations** and are well defined as strong predictors for good clinical response to EGFR tyrosine kinase inhibitors (EGFRi).

Cited by: 10 **Author:** Peter T. Harrison, Simon Vyse, Paul H. H...

Publish Year: 2020

Effectiveness of EGFR-TKIs in a Patient with Lung ...

<https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2018-0732>

Advanced detection technologies, such as next-generation sequencing, make possible the identification of **rare** variants of EGFR. This **case report** describes a patient with **lung adenocarcinoma harboring...**

Author: Yan Guan, Zhanshuai Song, Yan Li, H... **Publish Year:** 2019

BRIEF REPORT: Compound EGFR mutations and response to EGFR ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531043>

INTRODUCTION. Non-small-cell **lung** cancers (NSCLCs) containing **epidermal growth factor receptor (EGFR) mutations** are exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs). This is the **case** of the most common EGFR **mutations** affecting exon 18 (G719X), 19 (inframe deletions) and 21 (**L858R** and L861Q). However, the frequency of compound (i.e., double or complex) EGFR **mutations** - where ...

Cited by: 120 **Author:** Susumu Kobayashi, Hannah M. Canepa, ...

Publish Year: 2013

Better Progression-Free Survival in Elderly Patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266446>


Patients with **lung adenocarcinoma harboring** common **epidermal growth factor receptor (EGFR) mutations** usually have a good response rate (RR) and longer progression-free survival (PFS) to EGFR tyrosine kinase inhibitors (TKIs). However, the treatment efficacy to uncommon EGFR **mutations** remains controversial. We, therefore, performed a retrospective study, screening 2958 patients.

Cited by: 4 **Author:** Ming-Ju Tsai, Jen-Yu Hung, Mei-Hsuan L...

Publish Year: 2018

Epidermal growth factor receptor

Transmembrane Protein



The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family of extracellular protein ligands.


Wikipedia

People also search for

See all (5+)



HER2/neu



Receptor Tyrosine Kinase



Platelet-derived Growth Fa...



CD117



Beta-catenin

Data from: Wikipedia

Suggest an edit